May 8 |
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
|
May 1 |
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
|
Apr 24 |
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Apr 11 |
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
|
Apr 8 |
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
|